MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report

List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.

List prices for the leading multiple sclerosis drugs should be discounted by 25% to 80% to be considered cost effective, the Institute for Clinical and Economic Review concludes in a recently released final evidence report on the treatment class.

The discount recommendations and ICER’s report are intended to help inform MS drug contracting discussions between manufacturers and payers going forward. Payers have frequently flagged the cost of MS drugs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

US FDA Will Help States Apply To Import Cheaper Drugs From Canada

 
• By 

The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By 

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

More from Market Access

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By 

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.